Join us for an interesting and engaging discussion around IMNM, clinical trials, and COVID-19. Special guests: Dr. Andrew Mammen...
Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis VideoMyositis Support, , Featured, Inclusion Body Myositis (IBM)
The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
Today, Corbus Pharmaceuticals announced that the European Commission has approved orphan designation for lenabasum in the treatment of dermatomyositis...
We would like to let you know about a clinical research study that is available for patients diagnosed with...
Choose your language
- Myositis Awareness, September 2020
- Myositis Empower Walk, Join us 9/19/20
- The Grieving Project
- Explore Myositis
- Financial Assistance Program
- #ItsMyTurn: Becoming a Plasma Donor Hero
- Myositis Clinical Trials
- Myositis Webinars
- Upcoming Events
- Donate today!